Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0YWQ4)

• Drug Name: VB 1953 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM0YWQ4

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial DNA gyrase (Bact gyrase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Grepafloxacin	DMGLX0T	Chronic bronchitis	CA20.1	Approved	[3]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[4]
Levofloxacin	DMS60RB	Acute maxillary sinusitis		Approved	[4]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[4]
Norfloxacin	DMIZ6W2	Acute gonococcal cervicitis		Approved	[4]
Ozenoxacin	DM6KZMG	Impetigo	1B72	Approved	[5]
Sparfloxacin	DMB4HCT	Bacterial infection	1A00-1C4Z	Approved	[4]
Gemifloxacin	DMHT34O	Bacterial infection	1A00-1C4Z	Approved	[4]
Besifloxacin	DMPHXMI	Ocular inflammation	9C61.24	Approved	[6]
Finafloxacin	DMZEONG	Urinary tract infection	GC08	Approved	[7]

Drug(s) Targeting Bacterial DNA topoisomerase 4A (Bact parC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prulifloxacin	DMOK965	Urinary tract infection	GC08	Approved	[8]
Pazufloxacin	DMHXTAQ	Conjunctivitis	9A60	Phase 3	[9]
Sitafloxacin	DMTV5XC	Escherichia coli infection	1A03	Phase 2/3	[10]
JNJ-32729463	DMQD1GN	Community-acquired pneumonia	CA40.Z	Phase 2	[11]
TNP-2092	DM8DZKI	Skin and skin-structure infection	1F28-1G0Z	Phase 2	[12]
A-62824	DMJ6IMZ	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial DNA gyrase (Bact gyrase)	TTN6J5F	GYRA_STAAU; GYRB_STAAU	Inhibitor	[2]
Bacterial DNA topoisomerase 4A (Bact parC)	TTFK8YB	PARC_ECOLI	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03900676) Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Vyome Therapeutics.
• [3] Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
• [6] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [7] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [8] Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41.
• [9] Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7.
• [10] Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104.
• [11] Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.
• [12] Clinical pipeline report, company report or official report of TenNor Therapeutics.
• [13] Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6.